The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain — replacing the 2016 guideline — refined opioid prescribing recommendations based on accumulated evidence and addressed concerns that the 2016 guideline had been misapplied as rigid thresholds rather than patient-centered clinical guidance. Understanding the 2022 guideline framework and its clinical implementation reduces both undertreatment of legitimate pain and inappropriate prescribing contributing to opioid use disorder.
2022 CDC Guideline: Key Changes and Recommendations
The 2022 guideline is organized around 12 clinical recommendations across 4 domains: (1) Non-opioid therapies preferred for subacute and chronic pain — "Benefits and harms of opioids compared with non-opioid therapies for chronic pain are not fully understood." NSAIDs, SNRIs, physical therapy, CBT, and interventional procedures should be maximized before opioid initiation. (2) When opioids are used: lowest effective dose, short-duration for acute pain (≤3 days for most acute pain, ≤7 days for major surgery). Long-term opioid therapy for chronic non-cancer pain requires regular re-evaluation of continued benefit. The 2022 guideline dropped specific MME (morphine milligram equivalent) thresholds as absolute limits — individual risk-benefit assessment should guide decisions. (3) Risk assessment before and during treatment: ORT (Opioid Risk Tool): 5-item screening tool identifying low (score 0–3), moderate (4–7), and high (≥8) risk for opioid misuse — longer-term prescribing in moderate-high risk patients warrants more intensive monitoring. PDMP (Prescription Drug Monitoring Program): checking state PDMP before initiating and periodically during opioid therapy is now standard of care in most state regulations — identifies patients receiving opioids from multiple providers ("doctor shopping"). (4) Morphine milligram equivalents (MME): the 2022 guideline still notes increasing risk at higher MMEs but frames thresholds as clinical decision points requiring re-evaluation, not hard limits. Primary concern: concurrent benzodiazepine prescribing + opioids dramatically increases overdose mortality — avoid when possible.
Naloxone Co-Prescribing and Monitoring
Naloxone co-prescribing: the 2022 CDC guideline strongly recommends offering naloxone to patients prescribed opioids, particularly those at elevated overdose risk (high MME, concurrent CNS depressants, history of OUD). Evidence: naloxone access programs reduce opioid overdose mortality by 50% in community and clinical settings. Multiple states now mandate naloxone co-prescribing with high-dose opioid prescriptions. Urine drug screening (UDS): important monitoring tool but not a diagnostic test — understand limitations. Immunoassay UDS: high sensitivity, multiple false positives (poppy seeds → opiate screen, quinolones → false opioid, PPIs → false amphetamine). Confirmatory GC-MS required for clinical decisions about unexpected results. Testing frequency: at baseline and periodically — risk-stratified frequency (every 3 months for moderate-high risk, every 6–12 months for low risk). For clinical practices managing patients with chronic pain and opioid prescriptions, our laboratory supplies section includes urine collection cups and specimen processing supplies for drug monitoring programs.
